Creative Medical Technology Holdings Reports First Quarter 2025 Financial Results

Creative Medical Technology Holdings, Inc. reported its financial results for the first quarter of 2025, revealing a modest revenue of $3,000, a significant increase from zero revenue in the same period last year. The company recorded a gross profit of $1,800, marking its first positive gross profit since its inception. However, the company continues to face substantial operating losses, which totaled $1,660,478 for the quarter, compared to a loss of $1,123,147 in the prior year. The net loss for the quarter was $1,638,097, up from a loss of $1,041,544 in the same quarter of 2024.

The financial performance reflects a notable increase in operating expenses, which rose to $1,662,278 from $1,123,147 year-over-year. This increase was primarily driven by a 76% rise in research and development expenses, totaling $743,304, as the company continues to invest in its clinical trials and product development. Selling, general, and administrative expenses also increased by 32% to $888,397, attributed to higher marketing costs and other operational expenditures. The company’s cash position improved, with cash and cash equivalents reaching $7,702,867 as of March 31, 2025, compared to $5,940,402 at the end of 2024.

In terms of strategic developments, Creative Medical Technology has made significant strides in its clinical programs. The company is advancing its AlloStem™ platform, which has received FDA clearance for a Phase I/II clinical trial targeting chronic lower back pain. Additionally, the company has initiated patient recruitment for its Type I Diabetes clinical trial, which is expected to further enhance its product pipeline. The company also reported a successful warrant exercise transaction that generated approximately $3.7 million in net proceeds, which will be utilized for working capital and corporate purposes.

Operationally, the company has not yet achieved significant market penetration, as indicated by its minimal revenue generation. However, it has made progress in expanding its research capabilities and clinical trial activities. The company’s employee headcount remains stable, and it continues to focus on developing its proprietary technologies, including the ImmCelz™ platform, which utilizes reprogrammed immune cells for therapeutic applications. The company’s market share remains limited, but it is actively pursuing collaborations and partnerships to enhance its competitive position.

Looking ahead, Creative Medical Technology Holdings, Inc. remains focused on advancing its clinical trials and expanding its product offerings. The company acknowledges the challenges posed by market conditions and competition but is optimistic about the potential of its innovative therapies. Management has indicated that ongoing investments in research and development, along with strategic partnerships, will be critical to achieving long-term growth and operational success.